Clinical Trials Browser

Phase 2 × Has announcements × pemigatinib × Clear all

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Phase 2 Completed

47 enrolled 21 charts 1 FDA

Eosinophilia, Myeloproliferative Disorders

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Phase 2 Completed

147 enrolled 22 charts 2 FDA

Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma